Novo Nordisk has launched NovoCare Pharmacy in the United States, reducing the cost of its FDA-approved weight-loss medication, Wegovy (semaglutide), to $499 per month for cash-paying patients. This initiative is aimed at individuals without insurance or those whose commercial insurance does not cover obesity medications. The service includes home delivery of all dosage strengths.

This move follows Eli Lilly's recent price reduction for its weight-loss drug, Zepbound (tirzepatide), which is now available at $499 per month for certain dosages through the LillyDirect program.

These pricing strategies come as the FDA has declared the shortages of both Wegovy and Zepbound resolved, leading to increased availability of these medications.

On LinkedIn, discussions about affordability and access continue. While the lower self-pay pricing is a step forward, many argue that $499 per month still puts the medication out of reach for those who need it the most.

For more information, please visit NovoCare.